HIGH-DOSE CHEMOTHERAPY FOR RESISTANT GERM-CELL TUMORS - RECENT ADVANCES AND FUTURE-DIRECTIONS

被引:70
作者
MOTZER, RJ
BOSL, GJ
机构
[1] MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV SOLID TUMOR ONCOL, GENITOURINARY ONCOL SERV, NEW YORK, NY 10021 USA
[2] CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1992年 / 84卷 / 22期
关键词
D O I
10.1093/jnci/84.22.1703
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A review of the published literature shows that treatment with high-dose carboplatin and etoposide with autologous bone marrow transplantation results in durable complete responses (3-42 months, continuous at time of report) in about 10%-20% of heavily pretreated patients with cisplatin-resistant germ cell tumors and represents a curative therapy in patients who would otherwise die of their disease. In a recent follow-up study of 40 patients with refractory germ cell tumors, 15% (six) were alive and free of disease more than 24 months after treatment with high-dose carboplatin and etoposide with autologous bone marrow transplantation. The several studies that incorporated an oxazaphosphorine (usually cyclophosphamide) in the regimen strongly suggest that the addition of this third drug to high doses of carboplatin and etoposide results in a higher proportion of complete responses (35%, 23% durable) than carboplatin and etoposide alone (26%, 12% durable). Early intervention with high-dose chemotherapy and autologous bone marrow transplantation appears to reduce hematologic toxicity. Its role in the treatment of less heavily pretreated patients will depend on the definition of "cisplatin-resistant," which may encompass those who failed to respond to the drug or those who are judged not likely to respond. Studies to improve treatment efficacy and to lessen the burden of supportive care during hematopoietic reconstitution are ongoing and include the use of peripheral blood-derived stem cells.
引用
收藏
页码:1703 / 1709
页数:7
相关论文
共 74 条
[1]   GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUNCT TO AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR LYMPHOMA [J].
ADVANI, R ;
CHAO, NJ ;
HORNING, SJ ;
BLUME, KG ;
AHN, DK ;
LAMBORN, KR ;
FLEMING, NC ;
BONNEM, EM ;
GREENBERG, PL .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (03) :183-189
[2]  
BARBASCH A, 1983, CANCER TREAT REP, V67, P143
[3]  
BARNETT MJ, 1991, P ASCO, V10
[4]  
BIRON P, 1989, P ASCO, V8
[5]   THE TREATMENT OF ADVANCED TESTICULAR-CARCINOMA WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS MARROW SUPPORT [J].
BLIJHAM, G ;
SPITZER, G ;
LITAM, J ;
ZANDER, AR ;
VERMA, DS ;
VELLEKOOP, L ;
SAMUELS, ML ;
MCCREDIE, KB ;
DICKE, KA .
EUROPEAN JOURNAL OF CANCER, 1981, 17 (04) :433-441
[6]  
BOSL GJ, 1983, CANCER RES, V43, P3403
[7]   VAB-6 - AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR PATIENTS WITH GERM-CELL TUMORS [J].
BOSL, GJ ;
GLUCKMAN, R ;
GELLER, NL ;
GOLBEY, RB ;
WHITMORE, WF ;
HERR, H ;
SOGANI, P ;
MORSE, M ;
MARTINI, N ;
BAINS, M ;
MCCORMACK, P .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (10) :1493-1499
[8]   ROLE OF ETOPOSIDE-BASED CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR RELAPSING GERM-CELL TUMORS [J].
BOSL, GJ ;
YAGODA, A ;
GOLBEY, RB ;
WHITMORE, W ;
HERR, H ;
SOGANI, P ;
MORSE, M ;
VOGELZANG, N ;
MACDONALD, G .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) :423-428
[9]  
BOSL GJ, 1988, SEMIN ONCOL, V15, P339
[10]   ALTERNATING CYCLES OF ETOPOSIDE PLUS CISPLATIN AND VAB-6 IN THE TREATMENT OF POOR-RISK PATIENTS WITH GERM-CELL TUMORS [J].
BOSL, GJ ;
GELLER, NL ;
VOGELZANG, NJ ;
CAREY, R ;
AUMAN, J ;
WHITMORE, WF ;
HERR, H ;
MORSE, M ;
SOGANI, P ;
CHAN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :436-440